A 35-year-old woman with cystic fibrosis is started on tobramycin for chronic Pseudomonas aeruginosa lung infection. The prescriber wants to ensure optimal dosing and minimize nephrotoxicity. Which investigation is most appropriate to monitor for aminoglycoside-induced acute kidney injury?

## Aminoglycoside Nephrotoxicity: Early Detection and Monitoring ### Mechanism of Aminoglycoside Nephrotoxicity Aminoglycosides accumulate in proximal tubular cells via megalin-mediated endocytosis, causing lysosomal dysfunction and acute tubular necrosis (ATN). Nephrotoxicity is dose-dependent but can occur even with therapeutic dosing, especially with prolonged therapy. ### Investigation of Choice: Urine Biomarkers (Beta-2 Microglobulin and NAG) **Key Point:** Urine beta-2 microglobulin and N-acetyl-beta-D-glucosaminidase (NAG) are the most sensitive early markers of aminoglycoside-induced proximal tubular injury because: 1. They detect tubular damage **before** serum creatinine rises (which is a late marker of renal function loss) 2. Beta-2 microglobulin is reabsorbed by healthy proximal tubules; its presence in urine indicates tubular dysfunction 3. NAG is a lysosomal enzyme released from damaged proximal tubular cells 4. These biomarkers allow early drug discontinuation to prevent irreversible renal damage ### Comparison of Monitoring Strategies | Marker | Timing | Sensitivity | Clinical Use | |--------|--------|-------------|---------------| | **Urine β2-microglobulin & NAG** | Early (within 24–48 hrs) | High for tubular injury | Detect toxicity before Cr rises; guide drug continuation/discontinuation | | **Serum creatinine & eGFR** | Late (after 3–5 days) | Low for early detection | Reflects glomerular filtration; rises only after significant tubular loss | | **24-hr urine Cr clearance** | Late | Low for early detection | Cumbersome; reflects GFR, not tubular injury | | **FENa & urine osmolality** | Variable | Not specific for aminoglycosides | Used to differentiate prerenal vs. intrinsic AKI; not sensitive for early tubular toxicity | **High-Yield:** Serial urine NAG and beta-2 microglobulin are recommended in high-risk patients (prolonged therapy, renal impairment, advanced age) receiving aminoglycosides. ### Clinical Pearl Serum creatinine can remain normal or only mildly elevated despite significant proximal tubular damage because the kidney has substantial functional reserve. Urine biomarkers detect injury at the cellular level before functional loss is apparent. **Mnemonic:** **TUBULAR TOXINS** = **T**ubular biomarkers (β2-microglobulin, NAG) detect **U**rinary loss early; **B**iomarkers precede **U**rea/creatinine rise; **L**ate markers (Cr, eGFR) miss early **A**cute **R** tubular necrosis. ### Why Not the Alternatives? 1. **24-hour urine creatinine clearance and serum creatinine** — These reflect glomerular filtration rate, which is preserved until >50% of nephrons are damaged. They are late markers and miss early proximal tubular injury. 2. **Serum tobramycin trough level and eGFR** — Trough levels guide dosing to prevent toxicity but do not detect established tubular damage. eGFR is a late marker of renal dysfunction. 3. **FENa and urine osmolality** — These tests differentiate prerenal azotemia from intrinsic AKI but are not sensitive for detecting early aminoglycoside-induced tubular toxicity; they reflect hemodynamic status, not cellular injury. [cite:Harrison 21e Ch 297]